𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors

✍ Scribed by Kostas Kalbakis; Periklis Pappas; Charalambos Kouroussis; Lambros Vamvakas; Antonia Kalykaki; Nikolaos Vardakis; Martha Nikolaidou; Marios Marselos; Vassilis Georgoulias; Dimitris Mavroudis

Publisher
Springer
Year
2007
Tongue
English
Weight
391 KB
Volume
62
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I dose and sequencing study of peg
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie